Filing Details

Accession Number:
0001209191-18-007617
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-05 17:43:00
Reporting Period:
2018-02-01
Accepted Time:
2018-02-05 17:43:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610876 Jeffrey Chodakewitz C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp Gmda, Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-02-01 1,900 $167.44 52,524 No 4 S Direct
Common Stock Acquisiton 2018-02-02 1,796 $91.05 54,320 No 4 M Direct
Common Stock Disposition 2018-02-02 600 $165.23 53,720 No 4 S Direct
Common Stock Disposition 2018-02-02 996 $166.10 52,724 No 4 S Direct
Common Stock Disposition 2018-02-02 100 $168.06 52,624 No 4 S Direct
Common Stock Disposition 2018-02-02 100 $169.49 52,524 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-02-02 1,796 $0.00 1,796 $91.05
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,368 2026-02-01 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $165.23 (range $164.80 to $165.67).
  3. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $166.10 (range $165.81 to $166.43).
  5. The option vests in 16 quarterly installments from 2/2/2016.